Literature DB >> 21838960

Immune monitoring of Trichuris suis egg therapy in multiple sclerosis patients.

F Benzel1, H Erdur, S Kohler, M Frentsch, A Thiel, L Harms, K-P Wandinger, B Rosche.   

Abstract

Initial clinical trials using Trichuris suis eggs (TSO) in autoimmune diseases such as inflammatory bowel disease, revealed a striking suppressive effect on the autoimmune response. Here, we analysed the effect of TSO therapy on the course of multiple sclerosis (MS), as a Th1/Th17-associated autoimmune disease. Different immunological parameters in four patients with secondary progressive MS were surveyed during a 6-month therapy with TSO, focusing on the modulation of T-cell Th1-Th2 balance as well as on the innate immune response. We are able to show a slight downregulation of the Th1-associated cytokine pattern, especially relevant in interleukin (IL)-2 (P < 0.05 after 2 months of therapy), with a temporary increase of Th2-associated cytokines such as IL-4. Furthermore, mild eosinophily and changes in CD4+ and CD8+T cells and natural killer (NK) CD56 bright cell numbers were observed. The findings observed in this group of patients suggest that TSO therapy has a moderate immunomodulatory impact in MS.

Entities:  

Mesh:

Year:  2011        PMID: 21838960     DOI: 10.1017/S0022149X11000460

Source DB:  PubMed          Journal:  J Helminthol        ISSN: 0022-149X            Impact factor:   2.170


  24 in total

1.  Urinary Urea, Uric Acid and Hippuric Acid as Potential Biomarkers in Multiple Sclerosis Patients.

Authors:  Hanaa B Atya; Sahar A Ali; Mohamed I Hegazy; Fathia Z El Sharkawi
Journal:  Indian J Clin Biochem       Date:  2017-05-22

2.  Immunomodulation of liver injury by Ascaris suum extract in an experimental model of autoimmune hepatitis.

Authors:  Wheverton C Nascimento; Roeckson P Silva; Erica S Fernandes; Maria C Silva; Gabriela C Holanda; Patrícia A Santos; Mônica P Albuquerque; Vlaudia A Costa; Nicodemos T Pontes-Filho; Valdênia O Souza
Journal:  Parasitol Res       Date:  2014-06-21       Impact factor: 2.289

3.  Worming our way closer to the clinic.

Authors:  Matthew R Hepworth; Susanne Hartmann
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-07-15       Impact factor: 4.077

Review 4.  Nematodes and human therapeutic trials for inflammatory disease.

Authors:  D E Elliott; J V Weinstock
Journal:  Parasite Immunol       Date:  2017-04-18       Impact factor: 2.280

Review 5.  Tuftsin phosphorylcholine-a novel compound harnessing helminths to fight autoimmunity.

Authors:  Yahel Segal; Miri Blank; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

6.  Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial.

Authors:  John Fleming; Gianna Hernandez; Leslie Hartman; Jane Maksimovic; Sara Nace; Benjamin Lawler; Todd Risa; Thomas Cook; Rashmi Agni; Mark Reichelderfer; Christopher Luzzio; Loren Rolak; Aaron Field; Zsuzsanna Fabry
Journal:  Mult Scler       Date:  2017-10-24       Impact factor: 6.312

Review 7.  Helminth infections and host immune regulation.

Authors:  Henry J McSorley; Rick M Maizels
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

8.  Tuftsin-phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model.

Authors:  A Shemer; S Kivity; O Shovman; T Bashi; O Perry; A Watad; D Ben-Ami Shor; A Volkov; I Barshack; N L Bragazzi; A Krule; M Fridkin; H Amital; M Blank; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2018-08       Impact factor: 4.330

9.  Hookworm Treatment for Relapsing Multiple Sclerosis: A Randomized Double-Blinded Placebo-Controlled Trial.

Authors:  Radu Tanasescu; Christopher R Tench; Cris S Constantinescu; Gary Telford; Sonika Singh; Nanci Frakich; David Onion; Dorothee P Auer; Bruno Gran; Nikos Evangelou; Yasser Falah; Colin Ranshaw; Cinzia Cantacessi; Timothy P Jenkins; David I Pritchard
Journal:  JAMA Neurol       Date:  2020-09-01       Impact factor: 18.302

10.  Perspectives of People with Multiple Sclerosis About Helminth Immunotherapy.

Authors:  Sarah J Donkers; Megan C Kirkland; Marc Charabati; Lisa C Osborne
Journal:  Int J MS Care       Date:  2020 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.